BACKGROUND: Posttransplant lymphoproliferative disorder (PTLD) is a life-threatening complication of solid organ transplantation. Histologic heterogeneity and a lack of treatment standards have made evaluating clinical outcomes in specific patient populations difficult. This systematic literature review investigated the impact of the PTLD histologic subtype on survival in a large data set. METHODS: Case series were identified on PubMed with the search terms post-transplant lymphoproliferative disorder/disease, PTLD, and solid organ transplantation, with additional publications identified through reference lists. The patient characteristics, immunosuppressive regimen, treatment, survival, and follow-up time for 306 cases were extracted from 94 articles, and these cases were combined with 11 cases from Emory University Hospital. Patients with a recorded subtype were included in a Kaplan-Meier survival analysis (n 5 234). Cox proportional hazards regression analyses identified predictors of overall survival (OS) for each subtype and B-cell subgroup. RESULTS: OS differed significantly between monomorphic T-cell neoplasms (median, 9 months) and polymorphic, monomorphic B-cell, and Hodgkin-type neoplasms, for which the median OS was not reached (P 5 .0001). Significant differences in OS among B subgroups were not detected, but there was a trend toward decreased survival for patients with Burkitt-type PTLD. Kidney transplantation and a reduction of immunosuppression were associated with increased OS for patients with B-cell neoplasms in a multivariate analysis. Immunosuppression with azathioprine was associated with decreased OS for patients with T-cell neoplasms, whereas radiotherapy was associated with improved OS for patients with that subtype. CONCLUSIONS: The histologic subtype represents an important prognostic factor in PTLD, with patients with T-cell neoplasms exhibiting very poor OS. Possibly lower survival for certain subsets of patients with B-cell PTLD should be explored further and suggests the need for subtype-specific therapies to improve outcomes.
INTRODUCTION
Posttransplant lymphoproliferative disorder (PTLD) comprises a group of lymphoid disorders arising in the setting of immunosuppression after solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT). Reported cumulative incidences of PTLD range from 1% to 20% for SOT (depending on the transplanted organ), with the peak incidence occurring 30 to 72 months after transplantation, 1,2 and from 0.5% to 1.0% for HSCT, 3 with the peak incidence occurring 2 to 4 months after transplantation. 3, 4 Reports of PTLD-related mortality range from 30% to 60%, and this makes this entity a major life-threatening complication of transplantation. 5 Accordingly, much work has been devoted to deciphering an etiologic framework for this complex disease in terms of both biology and epidemiology. However, the relative rarity of the disease has made evaluating clinical outcomes in specific patient populations difficult because many analyses are limited by a small sample size.
Morphologically and molecularly heterogeneous, PTLD is broadly categorized into 4 groups: early PTLD (plasmacytic hyperplasia and infectious mononucleosis-like lesions), polymorphic PTLD, monomorphic PTLD (which includes all T-cell/natural killer cell neoplasms as well as most B-cell neoplasms), and classical Hodgkin lymphoma-like PTLD. 6 The treatment of PTLD often varies according to the subtype and from institution to institution, 7 and it is complicated by a difficult balance between the risks and benefits of reducing immunosuppression and the intensity of chemo-immunotherapy: they help to eradicate the malignancy but may increase the risks of treatment-related toxicity and organ rejection. For patients with CD201 monomorphic B-cell PTLD who do not respond to a reduction of immunosuppression alone, the monoclonal CD20 antibody rituximab has emerged in the last 15 years as a viable therapeutic option when it is given alone [8] [9] [10] or is given in combination with 11, 12 or followed by chemotherapy with regimens such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). 13 Studies of PTLD outcomes in the post-rituximab era have largely been limited to phase 2 trials investigating these regimens and single-center experiences. 14, 15 Although it seems reasonable that responses to therapeutic agents and survival in certain monomorphic PTLD subgroups would mirror those for the de novo lymphoid malignancies they resemble (eg, Burkitt or diffuse large Bcell lymphoma), data on subtype-specific outcomes remain limited, perhaps in part because such subgroup categorization may not be captured in epidemiologic data sets. Thus, we conducted a systematic literature review that focused on detailed case series to investigate the impact of the histologic subtype on survival for patients with PTLD after SOT.
MATERIALS AND METHODS

Systematic Literature Review
Case reports and series were identified on PubMed with the search terms post-transplant lymphoproliferative disorder/disease, PTLD, and solid organ transplantation, and this generated a pool of 194 articles. Additional publications identified through the reference lists of these articles were incorporated into the pool, and they were assessed by inclusion criteria for suitability, as shown in Figure 1 . The inclusion criteria were as follows: 1) articles published in English between January 1, 1974, and July 1, 2016, with a pathology diagnosis and survival details and 2) adult cases after SOT.
A total of 306 cases were extracted from 94 articles (listed in Supporting Table 1 ) and were combined with 11 cases from our institution. This study received a priori approval by Emory's institutional review board. The abstracted data included the patient characteristics (age and sex), transplanted organ or organs, immunosuppressive regimen, histologic subtype, initial PTLD treatment, response to treatment, time interval between the transplant and PTLD diagnosis (in months), time interval between the PTLD diagnosis and death (in months), and length of the follow-up after the PTLD diagnosis (in months). According to the description in the primary publication, histologic subtypes were coded as polymorphic, monomorphic B-cell, monomorphic T-cell, or Hodgkin-like (HL); there were no early PTLD cases identified in our review of published cases. Monomorphic B-cell neoplasms were also further subdivided into 4 subgroups: diffuse large B-cell lymphoma, Burkitt lymphoma, plasmacytoid, and other/unspecified.
Statistical Analysis
The univariate association of each aforementioned covariate with each of the 4 major subtypes (polymorphic, monomorphic B-cell, monomorphic T-cell, and HL neoplasms) and with the 4 subgroups of B-cell neoplasms was assessed with the chi-square test for categorical covariates and with an analysis of variance for numerical covariates.
Patients with recorded subtype information and reported survival on follow-up were included in the survival analysis (n 5 234). Univariate and multivariate Cox proportional hazards regression analyses were performed to identify predictors of overall survival (OS) for each subtype and B-cell subgroup. OS was defined as the time from diagnosis to death or last follow-up; those still alive were censored at the last follow-up. The multivariate model was fit by a backward variable selection method, and a level of significance (a) of .10 was applied as the removal criterion. Survival curves were constructed with the Kaplan-Meier method and compared with the logrank test. To evaluate the impact of changes in standard therapy over time on survival, we divided cases into eras by the year of publication: 1974-1999 to reflect the years before widespread rituximab use and 2000-2016, by which time rituximab was commonly used to treat other B-cell malignancies and the first retrospective analyses of its use for CD201 PTLD had been reported. 16, 17 A level of significance (a) of .05 was considered statistically significant. All statistical analyses were conducted with SAS version 9.4 with SAS macros and software developed at the Biostatistics and Bioinformatics Core at the Winship Cancer Institute. 18 Table 1 depicts the baseline characteristics and treatment information for the entire cohort of cases (n 5 234). In the cohort, 52.1% of the cases were B-cell monomorphic neoplasms (with diffuse large B-cell lymphoma being the most frequent subtype with 59 cases [48.4% of B neoplasms]), 28.6% were T-cell monomorphic neoplasms, 10.7% were HL, and 4.3% were polymorphic. Compared with patients with other subtypes, patients with HL PTLD were younger at diagnosis (mean age, 37 years; P 5 .001), and among patients with B-cell monomorphic PTLD, those with Burkitt-type PTLD were significantly younger (mean age, 37 years; P < .001); this mirrored incidence patterns seen in corresponding de novo lymphoma types. As might be expected, polymorphic cases were more likely to be treated with surgery and less likely to receive chemotherapy than most other subtypes. In comparison with other B-cell subgroups, treatment with chemotherapy was significantly more common for Burkitt-type PTLD (92.9%; P 5 .014). Univariate comparisons of variables among PTLD subtypes and among B-cell subgroups are shown in Tables 2  and 3 , respectively.
RESULTS
In the survival analysis, OS was significantly different between histological and immunophenotypic subtypes. Patients with monomorphic T-cell neoplasms had worse survival (median, 9 months), whereas the median OS was not reached for polymorphic, monomorphic Bcell, or HL PTLD (log-rank P 5 .0001; Fig. 2A ). The 2-year OS rates with 95% confidence intervals for each subtype were as follows: 35% (23.4%-46.9%) for monomorphic T-cell neoplasms, 70.0% (32.9%-89.2%) for polymorphic neoplasms, 60.6% (50.6%-69.2%) for monomorphic B-cell neoplasms, and 76.5% (51.9%-89.7%) for HL neoplasms. Significant differences in OS among B subgroups were not detected, but there was a trend toward decreased survival for patients with Burkitttype PTLD (Fig. 2B ). We found that although survival outcomes appeared to improve for all histologic subtypes in the modern, post-rituximab period, the prognosis for patients with T-cell neoplasms remained poor, regardless of the treatment era (Fig. 3) . The greatest improvement in survival was seen in the HL subtype: the 2-year overall OS was 100% in the 2000-2016 era but 67.5% (38.4%-85.1%) in the 1974-1999 era. The small number of total monomorphic B-cell cases in the pre-rituximab era (n 5 23) precluded us from comparing outcomes for B-cell subgroups between treatment eras. As shown in Table 4 , kidney transplantation and treatment with a reduction of immunosuppression were associated with increased OS in a multivariate analysis for patients with Bcell neoplasms. Immunosuppression with azathioprine was associated with decreased OS for patients with T-cell neoplasms, whereas treatment with radiotherapy was associated with improved OS for patients with that subtype (Table 5) .
DISCUSSION
To investigate outcomes in specific PTLD subtypes, we sought to increase the representation of relatively rare subgroups by aggregating clinical and survival data from published case series in our systematic review. This unconventional approach helped us to mitigate the dual problem of a small sample size, which often limits analyses derived from single-center experiences, and the lack of pathologic specificity, which plagues many larger epidemiologic databases. The potential limitations of our study include those inherent to any systematic review, including a publication bias and a study selection bias. Specifically, we suspect that the higher than expected frequency of monomorphic T-cell neoplasms in our data set may be due to a publication bias toward the presentation of more unusual cases. We performed a comprehensive systematic review of the literature, including a search of relevant publications cited by each source to address these issues where possible. Because of our focus on case series, our approach was also limited by publications that lacked a central pathology review or provided inadequate data for inclusion in survival analyses. Specifically, missing or incomplete data on an Epstein-Barr virus (EBV) association (27%) hindered our ability to reliably assess this as a factor in subtype-specific survival. Comprehensive, prospectively collected data in large cohort studies that include patients with PTLD are needed to meaningfully capture these clinical factors and assess their impact on survival. Nevertheless, our approach represents a large retrospective data set assembled to examine PTLD subtype-specific clinical factors, treatment patterns, and outcomes, and it provides provocative data for future investigation. Our finding that patients with monomorphic T-cell PTLD exhibited poor survival in comparison with patients with other subtypes is supported by a recent meta-analysis that examined T-cell PTLD alone. In that study, which included pediatric cases, the median OS for all 156 cases was only 6 months, with subgroup-specific OS (ie, OS for patients with hepatosplenic lymphoma, anaplastic lymphoma, primary cutaneous anaplastic lymphoma, or peripheral T-cell lymphoma not otherwise specified) ranging from 2 to 18 months. 19 The T-cell subtype was also found to be a negative prognostic factor for OS in a Swedish study of 135 PTLD cases (including 15 cases with T-cell neoplasms), with a hazard ratio of 3.52 (P < .001) in a multivariate Cox regression analysis. 20 Although not statistically significant, the trend toward decreased survival for patients with Burkitt-type monomorphic B-cell PTLD seen in our study merits investigation in larger data sets. The idea that Burkitt-type PTLD should be considered a discrete entity within B-cell PTLD, with clinicopathologic features that also distinguish it from sporadic, endemic, and immunodeficiencyassociated Burkitt lymphomas, has been posited in the pediatric setting. 21 Interestingly, although cases in that particular series uniformly exhibited aggressive clinical However, such models do not account for the significant proportion of PTLD cases in which the role of EBV is not readily apparent, such as neoplasms arising from T or natural killer cells, although the presence of EBV DNA in Tcell PTLD tumor cells has been described. 25 Disparities in the timing of the peak incidence between SOT and HSCT suggest differences in etiologic pathways as well. In fact, typical SOT-related PTLDs develop from recipient cells, whereas most HSCT-associated PTLDs arise from donor cells; this further adds to the complexity of characterizing oncogenesis in this heterogeneous disease. [26] [27] [28] Perhaps unsurprisingly, other major risk factors for PTLD development relate to modulations of the immune milieu. Reported risk factors in SOT include the transplantation of lymphoid-rich organs such as the lung and intestine and transplantation from an EBVseropositive donor to an EBV-seronegative recipient, whereas risk factors in HSCT include T-cell-depleted grafts, human leukocyte antigen mismatch, and primary immunodeficiency. 26, 29 The estimation of the intensity of pharmacological immunosuppression between individual patients and across clinical SOT protocols is challenging, and associations between immunosuppression and PTLD have been derived only indirectly from registry analyses and observational studies. 30 In both SOT and HSCT, T-cell-depleting agents such as antithymocyte globulin and the anti-CD3 monoclonal antibody OKT3 are associated with PTLD development. 15, [31] [32] [33] Interestingly, an increased PTLD risk has not been observed with alemtuzumab, 34 a monoclonal antibody directed against the CD52 marker present on both B-and T-cells, and this has led some to speculate that that drug's additional B-cell-depleting effect could serve to reduce the risk of B-cell PTLD. In the maintenance setting, the calcineurin inhibitor tacrolimus has been associated with an increased PTLD risk in several large studies, 31, 32, 35, 36 but mycophenolate mofetil does not appear to exert this same effect. 15, 35, [37] [38] [39] [40] Although the mechanisms underlying these differences in risk remain unclear, it is worth noting that mycophenolate acts to suppress both B-and T-cells, whereas the immunosuppressive effect of tacrolimus is more T-cell-specific.
Conversely, depending on the antiviral agent, prophylactic antiviral use after transplantation may reduce the risk of PTLD development up to 83%. 41 The combination of monitoring the serum EBV DNA load and adjusting immunosuppression is similarly associated with a lower incidence of PTLD after SOT. 42, 43 Indeed, a reduction of immunosuppression is a frequently used initial approach for PTLD that can reconstitute cytotoxic Tcell function against uncontrolled lymphoproliferation, with reported response rates as high as 45%. 44 It is difficult to evaluate the role of individual immunosuppressive agents and reduction-of-immunosuppression strategies in PTLD risk and outcomes, especially because transplant patients may receive a variety of drug combinations during induction, maintenance, and/or treatment for graft rejection. 45 Although the relatively small sample size in our multiple variable regression models limits their power, our results indicate that a reduction of immunosuppression is associated with improved OS in B-cell PTLD but not T-cell PTLD. These findings suggest subtypespecific differences in susceptibility to cytotoxic T-cell effects, which may in turn reflect etiologic differences in pathogenesis (eg, EBV-induced malignant transformation in B-cell neoplasms but not T-cell neoplasms). Moreover, the association of azathioprine with decreased OS in T-cell PTLD may implicate particular immunosuppressive agents as barriers to the eradication of certain PTLD subtypes. Our findings are supported by a large study of 230 cases from the French registry of PTLD occurring after renal transplantation; that study identified azathioprine as a factor associated with poor OS, but it did not show a subtypespecific association or survival differences based on histologic factors. 46 Although azathioprine's inhibition of purine nucleotide biosynthesis with suppression of DNA and RNA synthesis has been well described, the specific mechanism or mechanisms by which it downregulates B-cell and T-cell function to induce immunosuppression are less well characterized. In vitro and in vivo data suggest that azathioprine may interfere with CD28 costimulation of alloreactive T cells by blocking the guanosine triphosphatase Rac1, which results in activation of apoptotic pathways upon CD28-mediated signaling. 47 Furthermore, azathioprine may preferentially induce apoptosis in CD45RO memory T cells through suppression of the expression of the antiapoptotic protein BCL-XL; this thus offers a possible explanation for azathioprine's ability to induce tolerance to a foreign antigen (eg, of an organ graft). However, it remains unclear how the elimination of this T-cell population might contribute to a worse prognosis for patients with T-cell PTLD. To answer this and other complex questions surrounding the impact of the immunosuppressive regimen on subtype-specific outcomes, prospective epidemiologic studies are needed to link detailed clinical information with data from biologic specimens, including tumor tissue and longitudinally collected peripheral blood samples.
As in de novo lymphoid malignancies, subtypespecific survival in PTLD may also depend on responses to immunochemotherapeutic regimens. Importantly, better survival for patients with B-cell PTLDs may in part reflect improved treatment responses seen with rituximab treatment, which is unavailable to patients with PTLD subtypes without CD20 expression. In a retrospective, multicenter analysis of 80 patients with SOT-related PTLD who received a reduction of immunosuppression, those who received concomitant frontline rituximab-based therapy experienced improved 3-year progression-free survival and OS (70% and 73%, respectively) in comparison with those who did not (21% and 33%, respectively). 48 However, that study did not differentiate between subtypes of monomorphic PTLD. Three prospective phase 2 trials provided evidence that rituximab monotherapy has efficacy in CD20-positive PTLD, but all of these demonstrated relatively short time-to-progression intervals. [8] [9] [10] Accordingly, the prospective, multicenter PTLD-1 trial investigated a sequential treatment approach with 4 weeks of rituximab followed by chemotherapy with CHOP for SOT-related CD20-positive PTLD failing to respond to a reduction of immunosuppression. 13 Sixty percent of the patients (42 of 70) achieved either a complete response or a partial response after rituximab monotherapy, with the response rate improving to 90% (53 of 59) with a complete response rate of 68% upon the completion of sequential therapy. The median survival for responders was not reached at the time of the analysis, and a response to rituximab before chemotherapy was predictive of the time to progression and OS. EBV-associated disease was also found to be favorable in terms of the time to progression, and this further emphasizes rituximab's role in PTLD outcomes. Although we used the advent of widespread rituximab use as a cut point to analyze changes in subtypespecific survival over time, the most striking difference in survival between treatment eras occurred among patients with HL PTLD, a CD20-negative subtype that does not benefit from rituximab treatment. The sample sizes are admittedly small, but it is unclear what factors led to this apparent increase over time. Notably, none of the articles reported treatment with newer agents such as the CD30-targeting antibody-drug conjugate brentuximab vedotin. It is possible that this may reflect a shift in supportive care or diagnostic knowledge, but it may also lend support to the findings of Rosenberg et al, 49 who found that patients with HL PTLD who received chemotherapeutic regimens traditionally used for Hodgkin lymphoma experienced improved survival. That recent retrospective analysis used the Scientific Registry for Transplant Recipients and Surveillance, Epidemiology, and End Results databases to compare outcomes between HL PTLD and de novo Hodgkin lymphoma, and it highlighted several interesting ideas pertaining to PTLD subtypes. For patients with HL PTLD, the receipt of any chemotherapy was associated with a decreased hazard of death (hazard ratio, 0.36; P < .001), and patients who received nontraditional Hodgkin regimens had an increased hazard of death (adjusted hazard ratio, 2.01; P 5 .04) in comparison with those who received Hodgkin-specific chemotherapy regimens. To account for the fact that patients with HL PTLD would be more likely to die of nonlymphoma causes than patients without prior SOT (eg, graft failure), the authors calculated cumulative incidence curves of lymphoma-specific mortality, treating other causes of death as competing risks. Patients with HL PTLD exhibited a 5-year lymphoma-specific mortality rate of 23%, compared to 13% in patients with de novo Hodgkin lymphoma (P < .001). Taken together, these findings suggest that subtype-directed therapy remains an important consideration in PTLD, but lymphomaspecific survival with HL PTLD remains worse in comparison with its de novo counterpart. Additional studies using large data sets are needed to determine whether such conclusions hold true for other rare subgroups of monomorphic PTLD. An improved understanding of the underlying differences in the pathogenesis of PTLD subtypes and the outcomes of subtype-directed therapies in comparison with their de novo counterparts will be necessary to tailor appropriate treatments for each subtype.
In conclusion, our work lends credence to the emerging concept that the PTLD subtype carries major implications in terms of both prognosis and treatment options. Importantly, we show that patients with monomorphic T-cell PTLD suffer inferior survival in comparison with all other subtypes. Possibly lower survival for certain subsets of patients with monomorphic B-cell PTLD should also be explored further and suggests the need for subtype-specific therapies to improve outcomes. Multi-institution collaborative efforts could evaluate these associations in a larger number of cases with the necessary level of histologic discrimination. In general, performing meaningful studies of subtype-specific disparities in PTLD in the future will require the collection of biological specimens as well as clinical data to examine the effect of the PTLD subtype on differences in disease presentation, treatment selection, and patient outcomes.
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